Need for clarifying remote physiologic monitoring reimbursement during the COVID-19 pandemic: a respiratory disease case study

Robert Jarrin1,2,3, Meredith A. Barrett4, Leanne Kaye5, Sibel Sayiner5, Amanda von Leer6, Jennifer Johns5, Larissa D’Andrea6, Carlos Nunez2 and Andrey Ostrovsky6

The use of remote monitoring and virtual visits has accelerated to support socially-distanced patient care during the COVID-19 pandemic. Despite the necessity of this expansion, ambiguity in coding is hindering adoption and patient access, most notably for remote physiologic monitoring due to a lack of definition of the term “physiologic”. In this analysis, we describe the history of remote monitoring code development, present several examples in respiratory disease and other chronic conditions in which gaps and confusion remain and suggest ways to clarify and broaden coverage to ensure equitable access to remote monitoring.

INTRODUCTION
The use of remote monitoring to evaluate and manage patients with chronic illness has become even more important in the wake of COVID-19. Remote monitoring, which uses digital health technologies to monitor patient data from anywhere, allows patients and providers to manage the chronic disease without relying on in-person appointments. With remote monitoring, patients can self-manage their condition from home, and providers can leverage data on the patient’s condition to inform their clinical decision-making.

Prior to the COVID-19 pandemic, remote monitoring was gaining traction across several disease states, most notably heart disease, mental health, lung disease, and diabetes. COVID-19 accelerated the adoption of remote monitoring dramatically. With patients unable to see their providers in person, remote monitoring, telemedicine, telehealth, and virtual care saw a 20-fold increase in use1, and reimbursement for these services became a focal point for the Centers for Medicare and Medicaid Services (CMS). Remote monitoring is related but distinct from telemedicine by definition and modality in that it involves the interpretation of medical information without a direct, synchronous interaction between the practitioner and beneficiary.

Despite growing interest in the use of remote monitoring, ambiguity around reimbursement is still creating barriers to adoption2 and preventing the delivery of effective, socially distanced care for multiple conditions, which could exacerbate inequitable access to digital tools.

In the past several years, CMS has created multiple Current Procedural Terminology (CPT®) codes for remote monitoring services. Four CPT® codes now exist for the provision of “remote physiologic monitoring” services, but CMS has failed to define what it means by “physiologic”, causing providers and payers to question which technologies qualify for reimbursement.

Without clarity on whether a technology qualifies for reimbursement, providers are less able to implement tools that could significantly benefit patient care, lower cost, and increase access for underserved populations. While this is a problem during COVID-19 because of the need for social distancing, it will persist after the pandemic as well.

The current gaps in coding and reimbursement pose a particular problem for the remote treatment of respiratory disease. There are ~16 million people with chronic obstructive pulmonary disease (COPD) in the USA6 and just under 25 million with asthma7, accounting for $130 billion in direct and indirect costs annually for both COPD6 and asthma7. Acute and chronic lower respiratory diseases combined are the third leading cause of death8 in the USA. Furthermore, the social burden of asthma and COPD9 is demonstrated by the millions of days absent from work and school by both patients and caregivers.

In this analysis, we explore the history and use of remote monitoring codes for reimbursement, present several examples highlighting existing gaps in coding and reimbursement both in respiratory disease and other chronic conditions, and make recommendations for further clarifying and broadening coverage to enhance equitable access to remote monitoring.

OVERVIEW OF CPT® AND REMOTE MONITORING CODING
The American Medical Association (AMA) maintains and develops the CPT® code set. CPT® codes are descriptive terms used in reporting medical, surgical, and diagnostic procedures and services that are performed by physicians and other qualified healthcare professionals in the USA. CPT® codes form the basis for reimbursement, research, and tracking medical utilization. Although CPT® codes have existed for numerous remote medical services, until recently, codes to describe general remote monitoring of physiologic data did not exist.

In the 2018 Physician Fee Schedule final rule, CMS concluded that “remote patient monitoring” services could be a significant part of ongoing medical care and that recognition and separate payment for “these services” was to be done “as soon as practicable”.

1The Omega Concern, LLC, Washington, DC, USA. 2Department of Emergency Medicine, George Washington University, Washington, DC, USA. 3Department of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, DC, USA. 4ResMed Science Center, San Diego, CA, USA. 5Propeller Health, San Francisco, CA, USA. 6ResMed, San Diego, CA, USA. 7Social Innovation Ventures, Rockville, MD, USA. 8Email: andrey@socialinnovationventures.co

Published in partnership with Seoul National University Bundang Hospital
CPT\(^{\text{®}}\) collection and interpretation of physiologic data (i.e., “remote patient monitoring”) CMS chose to activate, cover, and pay for CPT\(^{\text{®}}\) Code 99091—a code predicated on collection and interpretation of physiologic data, which CMS referred to as remote patient monitoring. Around the same time, CPT\(^{\text{®}}\) approved three “remote physiologic monitoring” codes (CPT\(^{\text{®}}\) 99453, 99454, and 99457), which went into effect on January 1, 2019 (Table 1). In September 2018, CPT\(^{\text{®}}\) created a fourth “remote physiologic monitoring” code (CPT\(^{\text{®}}\) 99458) that went into effect on January 1, 2020. It is important to note that these codes represent remote physiological monitoring, but also (and arguably more importantly) treatment management services that go well beyond the review of medical device data. However, CMS still had not defined “physiologic”, as reflected in Table 1.

“PHYSIOLOGIC” LIMITATIONS: THE CHALLENGE OF REIMBURSEMENT GIVEN GENERAL TERMS The lack of definition of “physiologic” has created confusion within the reimbursement community, causing providers and payers to question which technologies and physiologic markers qualify for remote “physiologic” monitoring reimbursement, therefore limiting adoption.

The term “physiologic” appears nearly 80 times throughout the AMA CPT\(^{\text{®}}\) 2020 Professional Edition codebook. The CPT\(^{\text{®}}\) Editorial Panel publishes the annual codebook to report the rules and guidelines surrounding CPT\(^{\text{®}}\) codes and descriptors. Despite urgings by stakeholders for clarity, “physiologic” is not formally defined in the CPT\(^{\text{®}}\) manual, the CPT\(^{\text{®}}\) Coding Assistant, a coding “Resource and Coverage Guide”, AMA’s Digital Health Implementation Playbook, nor on any associated website.

CMS coverage and payment of remote physiologic monitoring In November 2018, CMS extended coverage and payment for CPT\(^{\text{®}}\) remote physiologic monitoring codes 99453, 99454, and remote physiologic monitoring treatment management services code 99457. In November 2019, CMS announced that it would adopt, cover, and pay CPT\(^{\text{®}}\) code 99458 for each “additional 20 min”, beginning January 1, 2020. In the Final Rule commentary\(^{11}\), CMS acknowledged the need for clarification of the term physiologic and indicated they would consider these issues in future rulemaking. However, as of September 2020, CMS has not issued regulatory, sub-regulatory, or clarifying policy specific to the entire suite of remote physiologic (9945X) monitoring codes. More broadly, the term physiologic does not have a formal definition by CMS within rule, policy, or even in its listing of chronic diseases and associated terms.

“PHYSIOLOGIC” AMBIGUITY: A RESPIRATORY DISEASE CASE STUDY There exists a multitude of examples where a narrow definition of physiologic limits the application of remote monitoring, which we describe briefly below. Here, we describe examples in respiratory disease that demonstrate the need for a broadened, clarified definition of physiologic. This respiratory exploration is proposed due to the prevalence and social and economic burden of COPD and asthma, prior published research in this area, provider confusion about coverage, and the relevance of the topic given COVID-19.

Propeller digital therapeutic Propeller is a Food and Drug Administration-cleared, digital therapeutic that combines inhaler sensors, companion mobile apps, predictive analytics, and monitoring and feedback to support self-management and clinical care for asthma and COPD\(^{12,13}\). Sensors
passively monitor the use of inhaled medications, capturing the date and time of each usage, and approximate geographic location (when paired with a smartphone). These signals provide an assessment of daily adherence to controller medication therapy and changes in the use of rescue medications, or short-acting beta-agonists (SABA), which are used for acute relief of asthma and COPD symptoms. Patients have access to these data through web dashboards and smartphone applications. Clinical teams can also access sensor-collected data through a web dashboard to inform clinical decisions such as medication adjustments and receive notifications about patients whose status may be declining.

**SABA use as a physiologic measure**

Determination of a patient’s respiratory status is made with a combination of clinical input, including physical examination focused on the work of breathing and chest auscultation, patient-reported outcomes and measures including spirometry, heart rate, respiratory rate, oxygen saturation, and exercise testing. We propose that the signals collected by the inhaler sensor provide an objective assessment of SABA use, providing physiological indicators of stable, worsening, or improving lung health.

SABA use is an important marker of respiratory disease status, specifically level of control, disease burden, and risk. Studies have shown that exacerbations—events characterized by a sudden worsening in symptoms requiring an oral corticosteroid, emergency department (ED) visit or hospitalization—may also be identified through increased use of SABA medication. In COPD, SABA overuse is associated with greater disease burden, and upward trends in use have been associated with an increased risk of moderate-to-severe exacerbations. Similar outcomes have been observed in asthma, where increased SABA use has been associated with worsening symptoms and acute exacerbations. Studies have shown that clinically validated asthma and COPD self-reported instruments, such as the Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), and COPD Assessment Test (CAT), are significantly correlated with SABA use. Lastly, SABA has also been incorporated into the Asthma Medication Ratio, which is a specific HEDIS criteria measure, and is a commonly tracked outcome reported in 68% of studies of exacerbations. Previously, SABA use could only be captured based on medication pharmacy fill records, patient-reported history, or patients remembering to bring in their medications with a dose counter, making this component of respiratory status require record-keeping and/or presentation to a clinician for assessment. Passive monitoring of SABA with sensors provides a more real-time and objective component of evaluating respiratory status remotely, enabling early intervention to avoid unnecessary exacerbations.

**Clinical benefit of respiratory monitoring**

Respiratory digital therapeutics have been studied in multiple randomized controlled trials and observational studies. Across these studies, significant improvements in asthma and COPD outcomes have been demonstrated in association with their use, including reduction in daytime and nighttime self-reported symptoms, reduction in SABA use, increase in the number of SABA-free days, improvement in asthma control as measured by the ACT, and improvement in adherence to controller medications. These benefits have been observed in diverse participants, including underserved patients with both asthma and COPD. Significant reduction in acute healthcare utilization, including ED visits and hospitalization events, has been demonstrated for both asthma and COPD.

**Ambiguity in multiple disease states**

In other disease states, a similar promise yet ambiguity exists. In mental health, codes to support remote cognitive behavioral therapy are being developed; however, they do not necessarily cover other emerging signals, such as monitoring of smartphone usage or activity patterns, which may provide early indicators of depressive, anxious, or other pathologic behaviors. For Parkinson’s disease, wearable sensors offer promise in remotely monitoring motor fluctuations, immobility, and tremors, which can identify treatable symptoms such as dyskinesia and bradykinesia, but may not be covered by traditional physiologic monitoring codes.

These signals from multiple disease states demonstrate that digital health deployed for remote monitoring can serve as an important tool for medical practitioners, specialists, and clinicians to assist patients living with a multitude of conditions. It is therefore in the interest of those medical professionals who employ the use of remote monitoring technologies to accurately understand medical diagnostic and therapeutic services, particularly in the context of coding, coverage, and payment.

**REGULATORY CLARITY IS NEEDED**

Without any definition or clarification by AMA/CPT, CMS, or a medical society that formally excludes digital health technologies as a valid mechanism by which to capture physiologic markers for purposes of remote physiologic monitoring, there is no conclusive exclusion to the broad use of the term “physiologic”.

CMS may at any given time produce regulatory or sub-regulatory policy guidance clarifying their position. In the absence of authorities limiting their power, such as national coverage determinations, the contractors in any one of the 12 Medicare Administrative Contractors regions, acting under their specific geographic jurisdiction, may at their discretion deny claims based on their particular opinion or other arbitrary factors. CPT® code reimbursements are therefore vulnerable given the lack of clear definitions.

As digital health innovation proliferates, CPT® should continue to explore code gaps and create additional remote monitoring codes that describe other ways to evaluate patient status. As announced publicly by CPT® in anticipation of the CPT® Editorial Panel Meeting in October 2020, several applications to create new codes have been submitted for consideration, including one submitted by Propeller Health for Remote Respiratory Status Monitoring Services.

**CONCLUSION**

Based on all of the foregoing, including medical practice and evidence, “physiologic”, as used by CPT® codes for “Remote Physiologic Monitoring” should encompass these services. Inhaler sensors, used in conjunction with medicines and provider services, satisfy the professional and technical requirements for remote patient monitoring and remote physiologic monitoring CPT® codes.

As the US progresses through the COVID-19 pandemic, remote monitoring and other forms of virtual care will become increasingly critical to delivering effective healthcare while reducing infection risk and patient access to these tools should be equitable. An important step in addressing equity is to ensure that systemic reimbursement barriers, like the ambiguity of the definition of “physiologic”, do not disproportionately affect beneficiaries of public insurance more than those with commercial insurance or who are paying cash. In addition, temporary waivers, such as lifting geographic care site restrictions or administrative sanctions for providers who reduce or waive cost-sharing obligations, could temporarily incentivize providers.

Increased utilization of virtual care in healthcare, which has been implemented on an emergency basis during the COVID-19 pandemic, now needs to be integrated permanently. Chronic
respiratory disease care is just one example of the many conditions that could benefit from expanded access to remote monitoring.

DATA AVAILABILITY

Data in this paper are derived from public resources and published literature.

Received: 6 October 2020; Accepted: 8 February 2021;
Published online: 12 March 2021

REFERENCES

1. Mosnaim, G. S., Stempel, H., Sickle, D. V. & Stempel, D. A. The adoption and implementation of digital health care in the post–COVID-19 era. J. Allergy Clin. Immunol. Pract. 8, 2484–2486 (2020).
2. Hoffman, D. A. Increasing access to care: telehealth during COVID-19. J. Law Biosci. 7, Issa043 (2020).
3. Keesara, S., Jonas, A. & Schulman, K. Covid-19 and health care digital revolution. N. Engl. J. Med. https://doi.org/10.1056/NEJMp2008325 (2020).
4. Centers for Disease Control and Prevention (CDC). Employment and activity limitations among adults with chronic obstructive pulmonary disease—United States. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a1.htm (2013).
5. Centers for Disease Control and Prevention (CDC). Most recent national asthma data. CDC. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm (2020).
6. Guarascio, A. J., Ray, S. M., Finch, C. K. & Self, T. H. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clin. Outcomes Res. 5, 235–245 (2013).
7. Nurmagambetov, T., Kuwahara, R. & Garbe, P. The economic burden of asthma in the United States, 2008–2013. Ann. Am. Thorac. Soc. 15, 348–356 (2018).
8. Centers for Disease Control and Prevention (CDC). FastStats. https://www.cdc.gov/faststats/ (2020).
9. Akinbami, L. J., Moorman, J. E. & Liu, X. Asthma prevalence, health care use, and mortality: United States, 2005–2009. Natl. Health Stat. Rep. 32, 1–14 (2011).
10. Chronic Obstructive Pulmonary Disease (COPD). COPD Costs. https://www.cdc.gov/copd/infographics/copd-costs.html (2019).
11. Federal Register. Medicare Program; CY 2020 Revisions to Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies; Medicare Shared Savings Program Requirements; Medicaid Promoting Interoperability Program Requirements for Eligible Professionals; Establishment of an Ambulance Data Collection System; Updates to the Quality Payment Program; Medicare Enrollment of Opioid Treatment Programs and Enhancements to Provider Enrollment Regulations Concerning Improper Prescribing and Patient Harm; and Amendments to Physician Self-Referral Law Advisory Opinion Regulations Final Rule; and Coding and Payment for Evaluation and Management, Observation and Provision of Self-Administered Esketamine Interim Final Rule. https://www.federalregister.gov/documents/2019/11/15/2019-24086/medicare-program-cy-2020-revisions-to-payment-policies-under-the-physician-fee-schedule-and-otherinp-1284 (2019).
12. Merchant, R. K., Inamdar, R. & Quade, R. C. Effectiveness of population health management using the propeller health asthma platform: a randomized clinical trial. J. Allergy Clin. Immunol. Pract. 4, 455–463 (2016).
13. Chen, J. et al. Passive monitoring of short-acting beta-agonist use via digital platform in patients with chronic obstructive pulmonary disease: quality improvement retrospective analysis. JIMIR Res. 3, e13286 (2019).
14. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma—Summary Report 2007. J. Allergy Clin. Immunol. 120, S94–S138 (2007).
15. Van Sickle, D., Magzamen, S., Truelove, S. & Morrison, T. Remote monitoring of inhaled bronchodilator use and weekly feedback about asthma management: an open-group, short-term pilot study of the impact on asthma control. PLoS ONE 8, e55335 (2013).
16. Jenkins, C. R. et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm. Med. 15, 97 (2015).
17. Sumino, K. et al. Use of a remote inhaler monitoring device to measure change in inhaler use with chronic obstructive pulmonary disease exacerbations. J. Aerosol Med. Pulm. Drug Deliv. 31, 191–198 (2018).
18. Patel, M. et al. Predictors of severe exacerbations, poor asthma control, and β-agonist overuse for patients with asthma. J. Allergy Clin. Immunol. Pract. 2, 751–758 (2014).
19. Anderson, W. C. et al. Assessing asthma control: comparison of electronic-recorded short-acting beta-agonist rescue use and self-reported use utilizing the short-acting beta-agonist use as a measure of asthma control. J. Asthma 1–5 https://doi.org/10.1080/02777903.2019.1687715 (2019).
20. Santanello, N. C., Zhang, J., Seidenberg, B., Reiss, T. F. & Barber, B. L. What are minimal important changes for asthma measures in a clinical trial? Eur. Respir. J. 14, 23–27 (1999).
21. Gondalia, R., Bender, B. G., Theye, B. & Stempel, D. A. Higher short-acting beta-agonist use is associated with greater COPD burden. Respir. Med. 158, 110–113 (2019).
22. Schatz, M. et al. The controller-to-total asthma medication ratio is associated with patient-centered as well as utilization outcomes. Chest 130, 43–50 (2006).
23. NCQA. Medication management for people with asthma and asthma medication ratio. https://www.ncqa.org/hedis/measures/medication-management-for-people-with-asthma-and-asthma-medication-ratio/.
24. Fulhargie, A. et al. Asthma outcomes: exacerbations. J. Allergy Clin. Immunol. 129, 534–548 (2012).
25. Barrett, M., Combs, V., Su, J. G., Henderson, K. & Tuffli, M. AIR Louisville: addressing asthma with technology, crowdsourcing, cross-sector collaboration, and policy. Health Aff. 37, 525–534 (2018).
26. Lin, N. Y. et al. Telehealth delivery of adherence and medication management system improves outcomes in inner-city children with asthma. Pediatr. Pulmonol. 55, 858–865 (2020).
27. Chan, A. H. Y. et al. The effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trial. Lancet Respir. Med. 3, 210–219 (2015).
28. Van Sickle, D. V., Barrett, M., Humblet, O., Henderson, K. & Hogg, C. Randomized, controlled study of the impact of a mobile health tool on asthma SABA use, control and adherence. Eur. Respir. J. 48, PA1018 (2016).
29. Alshabani, K. et al. Electronic inhaler monitoring and healthcare utilization in chronic obstructive pulmonary disease. J. Telemed. Telecare https://doi.org/10.1177/1357633819850404 (2019).
30. Mosnaim, G. S. et al. The impact of patient self-monitoring via electronic medication monitor and mobile app plus remote clinician feedback on adherence to inhaled corticosteroids: a randomized controlled trial. J. Allergy Clin. Immunol. Pract. https://doi.org/10.1016/j.jaip.2020.10.064 (2020).
31. Foster, J. M. et al. Inhaler reminders improve adherence with controller treatment in primary care patients with asthma. J. Allergy Clin. Immunol. 134, 1260–1268.e3 (2014).
32. Merchant, R. et al. Impact of a digital health intervention on asthma resource utilization. World Allergy Organ. J. 11, 28 (2018).
33. Mohr, D. C. et al. A randomized noninferiority trial evaluating remotely-delivered stepped care for depression using internet cognitive behavioral therapy (CBT) and telephone CBT. Behav. Res. Ther. 123, 103485 (2019).
34. Ben-Zeev, D. et al. CrossCheck: Integrating self-report, behavioral sensing, and smartphone use to identify digital indicators of psychotic relapse. Psychiatr. Rehabil. J. 40, 266–275 (2017).
35. Rovini, E., Maremmani, C. & Cavallo, F. How wearable sensors can support Parkinson’s disease diagnosis and treatment: a systematic review. Front. Neurosci. 11, 555 (2017).
36. CPT Editorial Panel. CPT October Editorial Panel Meeting. American Medical Association https://www.ama-assn.org/about/cpt-editorial-panel/cpt-october-editorial-panel-meeting (2020).

ACKNOWLEDGEMENTS

Funding for this work was provided by ResMed.

AUTHOR CONTRIBUTIONS

R.J., M.A.B., L.K., and A.O. contributed to the conception, design, analysis and interpretation of the data, and drafted the manuscript. S.S., A.V.L., J.J., L.D.A., and C.N. contributed to the conception, design, and critical review of the manuscript. All authors approve of the completed version and are accountable for all aspects of the work.

COMPETING INTERESTS

The authors declare the following competing interests: A.O. is an advisor to ResMed. R.J. is an Advisor to the American Medical Association (AMA) Digital Medical Payment Program; Cy 2020 Revisions to Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies; Medicare Shared Savings Program Requirements; Medicaid Promoting Interoperability Program Requirements for Eligible Professionals; Establishment of an Ambulance Data Collection System; Updates to the Quality Payment Program; Medicare Enrollment of Opioid Treatment Programs and Enhancements to Provider Enrollment Regulations Concerning Improper Prescribing and Patient Harm; and Amendments to Physician Self-Referral Law Advisory Opinion Regulations Final Rule; and Coding and Payment for Evaluation and Management, Observation and Provision of Self-Administered Esketamine Interim Final Rule. https://www.federalregister.gov/documents/2019/11/15/2019-24086/medicare-program-cy-2020-revisions-to-payment-policies-under-the-physician-fee-schedule-and-otherinp-1284 (2019).

npj Digital Medicine (2021) 50

Published in partnership with Seoul National University Bundang Hospital
Advisory Group (DMPAG) and a paid strategic advisor to ResMed. M.B., L.K., C.N., L.D., A., and A.V.L. are full-time employees of ResMed. M.B. and L.K. are former employees of Propeller Health. S.S. and J.J. are full-time employees of Propeller Health.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to A.O.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021